Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

European Congress on Obesity 2026.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Engineered oesophagus transplantation in a pig model.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Liquid biopsy combined with machine learning predicts early detection in liver disease.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Diet-microbiome associations.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Gut microbiota induce browning of white adipose tissue.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Drug approvals in 2025 in gastroenterology and hepatology.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Synthetic data generation: challenges and perspectives for gastrointestinal medicine.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Positive results for daraxonrasib for previously treated metastatic pancreatic cancer.

Nature reviews. Gastroenterology & hepatology·2026

Same journal

Dietary perturbation and microbial adaptation in the gut.

Nature reviews. Gastroenterology & hepatology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 20, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Targeting hyperactive tRNA modification improves anti-PD1 efficacy

Eleni Kotsiliti¹

¹Nature Reviews Gastroenterology & Hepatology, . nrgasthep@nature.com.

Nature Reviews. Gastroenterology & Hepatology

|November 23, 2022

Summary

No abstract available in PubMed .

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Experiment Videos

Last Updated: Aug 20, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019